利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.046 秒)

    CDIM binding proteins and uses thereof
    7.
    发明授权
    CDIM binding proteins and uses thereof 有权
    CDIM结合蛋白及其用途

    公开(公告)号：US09409976B2

    公开(公告)日：2016-08-09

    申请号：US13763398

    申请日：2013-02-08

    申请人： Nelson N. H. Teng ,  Neelima M. Bhat ,  Marcia M. Bieber ,  Bruce A. Keyt

    发明人： Nelson N. H. Teng ,  Neelima M. Bhat ,  Marcia M. Bieber ,  Bruce A. Keyt

    IPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/30

    CPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/734 ,  C07K2317/92

    摘要： The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.

    摘要翻译： 本公开涉及细胞死亡诱导分子（“CDIM”）结合蛋白及其药物组合物。 特别地，本公开提供了可用于选择性消耗和杀死B细胞的CDIM结合蛋白，所述B细胞包括肿瘤性B细胞以及不具有表达CDIM样抗原的B细胞来源的肿瘤细胞。 此外，本公开包括编码所公开的抗原结合蛋白的多核苷酸，以及用于制备其的表达系统。 此外，本公开包括通过施用CDIM结合蛋白来治疗患有B细胞增殖和介导的疾病的患者的方法以及用于鉴定结合CDIM的蛋白质的诊断测定法。 本公开进一步考虑用于鉴定可用CDIM结合蛋白治疗的患者群体的诊断测定。

    Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
    8.
    发明授权
    Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids 失效
    具有拮抗性质的血管内皮细胞生长因子的变体，编码其的核酸和包含这些核酸的宿主细胞

    公开(公告)号：US06750044B1

    公开(公告)日：2004-06-15

    申请号：US08734443

    申请日：1996-10-17

    申请人： Bruce A. Keyt ,  Francis Hung Nguyen ,  Napoleone Ferrara

    发明人： Bruce A. Keyt ,  Francis Hung Nguyen ,  Napoleone Ferrara

    IPC分类号： A61K3819

    CPC分类号： A61K38/1866 ,  C07K14/52

    摘要： The present invention involves the preparation of vascular endothelial growth factor (VEGF) antagonist molecules comprising variant VEGF polypeptides which are capable of binding to and occupying cell surface VEGF receptors without inducing a VEGF response, thereby antagonizing the biological activity of the native VEGF protein. Specifically, the variant VEGF polypeptides of the present invention comprise modifications of at least one cysteine residue in the native VEGF sequence, thereby inhibiting the ability of the variant polypeptide to dimerize through the formation of disulfide bonds. The present invention is further directed to methods for preparing such variant VEGF antagonists and to methods, compositions and assays utilizing such variants for producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from the native VEGF protein.

    摘要翻译： 本发明涉及制备包含变体VEGF多肽的血管内皮生长因子（VEGF）拮抗剂分子，其能够结合并占据细胞表面VEGF受体而不诱导VEGF应答，从而拮抗天然VEGF蛋白的生物学活性。 具体地，本发明的变体VEGF多肽包含天然VEGF序列中至少一个半胱氨酸残基的修饰，从而通过形成二硫键来抑制变体多肽二聚的能力。 本发明进一步涉及制备这种变体VEGF拮抗剂的方法以及利用这些变体产生具有不同于天然VEGF蛋白的治疗和药理学性质的药物活性物质的方法，组合物和测定法。

    Tissue plasminogen activator variants with decreased clearance
    10.
    发明授权
    Tissue plasminogen activator variants with decreased clearance 失效
    组织纤溶酶原激活物变异体具有降低的清除率

    公开(公告)号：US5338546A

    公开(公告)日：1994-08-16

    申请号：US33612

    申请日：1993-03-16

    申请人： William F. Bennett ,  Bruce A. Keyt ,  Mark J. Zoller

    发明人： William F. Bennett ,  Bruce A. Keyt ,  Mark J. Zoller

    IPC分类号： A61K38/00 ,  C12N9/72 ,  C12N15/58 ,  C12N9/64 ,  A61K37/547 ,  C12N15/00

    CPC分类号： C12N9/6459 ,  C12Y304/21069 ,  A61K38/00

    摘要： Biologically active tissue plasminogen activator (t-PA) variants with decreased clearance as compared to wild-type t-PA are prepared, including variants that have one or more amino acid alterations in at least the kringle-1 and/or kringle-2 domain(s) of the molecule. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the DNA sequences and host cells transformed with the expression vectors. The variants may be used in pharmaceutical preparations to treat a vascular disease or condition, or to prevent fibrin deposition or adhesion formation or reformation in mammals.

    摘要翻译： 制备与野生型t-PA相比具有降低的清除率的生物活性组织纤溶酶原激活物（t-PA）变体，包括在至少kringle-1和/或kringle-2结构域中具有一个或多个氨基酸改变的变体 （s）。 可以制备编码变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 这些变体可用于药物制剂中以治疗血管疾病或病症，或用于预防哺乳动物中纤维蛋白沉积或粘附形成或重组。